Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Net Cash Flow (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Net Cash Flow for 4 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 449.69% to -$1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, up 411.4% year-over-year, with the annual reading at $5.3 million for FY2025, 411.4% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$1.2 million at bioAffinity Technologies, down from $6.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $13.3 million in Q3 2022, with the low at -$3.8 million in Q3 2023.
  • Average Net Cash Flow over 4 years is $331820.7, with a median of -$737107.5 recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 15450.34% in 2025, while the deepest fall reached 449.69% in 2025.
  • Over 4 years, Net Cash Flow stood at -$1.9 million in 2022, then increased by 9.47% to -$1.7 million in 2023, then surged by 120.66% to $348711.0 in 2024, then tumbled by 449.69% to -$1.2 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$1.2 million, $6.9 million, and $358129.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.